2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
1982
Clonidine in the treatment of Tourette syndrome: a review of data.
Leckman JF, Cohen DJ, Detlor J, Young JG, Harcherik D, Shaywitz BA. Clonidine in the treatment of Tourette syndrome: a review of data. Advances In Neurology 1982, 35: 391-401. PMID: 6756089.Peer-Reviewed Original ResearchConceptsTS patientsLong-term symptomatic improvementPathophysiology of TSDouble-blind trialEfficacy of clonidineMinority of patientsGrowth hormone releasePrimary pathogenic importanceMinimal side effectsSymptomatic improvementBlood pressureProfile of responseNoradrenergic mechanismsMHPG levelsTherapeutic responseHormone releaseClonidinePathogenic importanceAcute dosesSide effectsTourette syndromeBehavioral symptomsPharmacologic investigationsNeurochemical systemsPatients